Inicio
Detalle del título uniforme
Hormones
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (4)
Clasificado(s) por (Año de edición descendente) Refinar búsqueda
Título : Human kallikrein 10 in surgically removed human pituitary adenomas Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2015 Títulos uniformes : Hormones Idioma : Inglés (eng) Palabras clave : Human kallikrein 10 immunohistochemistry pathology pituitary adenoma prognostic marker Resumen : Objective: Human kallikrein-like peptidase 10 (KLK10), a serine protease, plays an important role in the regulation of cell proliferation and tumor growth. In this work, we investigated KLK10 immunoexpression in various types of surgically removed human pituitary tumors. Design: Specimens were fixed in formalin and embedded in paraffin. Immunostaining was performed by the streptavidin-biotin-peroxidase complex protocol using the LSAB+ Kit and a KLK10-specific rabbit polyclonal antibody. Results: Results showed that both treated and untreated prolactin-producing pituitary adenomas and carcinomas as well as TSH-producing pituitary adenomas and carcinomas were conclusively immunopositive for KLK10. Immunostaining was mainly localized in the cytoplasm and was clearly visible in many adenoma cells. In various other tumor types (oncocytoma, gonadotroph, somatotroph adenomas, and carcinomas), cytoplasmic immunopositivity was mild to moderate and seen only in a few unevenly distributed adenoma cells. Immunopositivity in the nuclei of various tumor types, as well as dual cytoplasmic and nuclear localization of KLK10 in some of the tumor types, was an intriguing finding. Immunoexpression in GH-producing adenomas exposed to octreotide, a long-acting somatostatin analog, was significantly increased when compared to unexposed GH-producing tumors. Conclusion: More studies are needed to ascertain the role of KLK10 in pituitary tumor development, prognosis, and progression. The question of whether genetic abnormalities and the microenvironment can affect KLK10 immunoexpression should also be investigated. Mención de responsabilidad : Fabio Rotondo, Antonio Di Ieva, Kalman Kovacs, Michael D Cusimano, Luis V Syro, Eleftherios P Diamandis, George M Yousef Referencia : Hormones (Athens). 2015 Apr-Jun;14(2):272-9. DOI (Digital Object Identifier) : 10.14310/horm.2002.1558. PMID : 25553760 En línea : http://www.hormones.gr/8536/article/human-kallikrein-10-in-surgically-removed%E2 [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3874 Human kallikrein 10 in surgically removed human pituitary adenomas [documento electrónico] / Luis Vicente Syro Moreno, . - 2015.
Obra : Hormones
Idioma : Inglés (eng)
Palabras clave : Human kallikrein 10 immunohistochemistry pathology pituitary adenoma prognostic marker Resumen : Objective: Human kallikrein-like peptidase 10 (KLK10), a serine protease, plays an important role in the regulation of cell proliferation and tumor growth. In this work, we investigated KLK10 immunoexpression in various types of surgically removed human pituitary tumors. Design: Specimens were fixed in formalin and embedded in paraffin. Immunostaining was performed by the streptavidin-biotin-peroxidase complex protocol using the LSAB+ Kit and a KLK10-specific rabbit polyclonal antibody. Results: Results showed that both treated and untreated prolactin-producing pituitary adenomas and carcinomas as well as TSH-producing pituitary adenomas and carcinomas were conclusively immunopositive for KLK10. Immunostaining was mainly localized in the cytoplasm and was clearly visible in many adenoma cells. In various other tumor types (oncocytoma, gonadotroph, somatotroph adenomas, and carcinomas), cytoplasmic immunopositivity was mild to moderate and seen only in a few unevenly distributed adenoma cells. Immunopositivity in the nuclei of various tumor types, as well as dual cytoplasmic and nuclear localization of KLK10 in some of the tumor types, was an intriguing finding. Immunoexpression in GH-producing adenomas exposed to octreotide, a long-acting somatostatin analog, was significantly increased when compared to unexposed GH-producing tumors. Conclusion: More studies are needed to ascertain the role of KLK10 in pituitary tumor development, prognosis, and progression. The question of whether genetic abnormalities and the microenvironment can affect KLK10 immunoexpression should also be investigated. Mención de responsabilidad : Fabio Rotondo, Antonio Di Ieva, Kalman Kovacs, Michael D Cusimano, Luis V Syro, Eleftherios P Diamandis, George M Yousef Referencia : Hormones (Athens). 2015 Apr-Jun;14(2):272-9. DOI (Digital Object Identifier) : 10.14310/horm.2002.1558. PMID : 25553760 En línea : http://www.hormones.gr/8536/article/human-kallikrein-10-in-surgically-removed%E2 [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3874 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000454 AC-2015-007 Archivo digital Producción Científica Artículos científicos Disponible Microvessel density and VEGF expression in pituitaries of pregnant women / Jorge Hernando Donado Gómez ; Luis Vicente Syro Moreno
Título : Microvessel density and VEGF expression in pituitaries of pregnant women Tipo de documento : documento electrónico Autores : Jorge Hernando Donado Gómez, ; Luis Vicente Syro Moreno, Fecha de publicación : 2013 Títulos uniformes : Hormones Idioma : Inglés (eng) Palabras clave : Angiogenesis Immunohistochemistry Pituitary Pregnancy Vascular endothelial growth factor Resumen : Objective: In pregnant women, the pituitary is enlarged and the prolactin (PRL) secreting cells increase in size and number. This PRL cell hyperplasia is associated with hyperprol-actinemia. The aim of the present work was to investigate adenohypophysial vascularization and immunoexpression of vascular endothelial growth factor (VEGF) in pituitaries of pregnant and post-partum women and compare the results with age-matched adenohypophyses of non pregnant women who had no endocrine diseases. Design: Pituitaries (n=18) obtained by autopsy from female patients of reproductive age who had died during pregnancy, after abor- tion or during post-partum were immunostained for CD-34 and VEGF using the streptavidin-biotin-peroxidase complex method. Results: The results showed that microvessel densities and VEGF immunoexpression in the adenohypophyses of pregnant and post-partum women were similar to those found in the control pituitaries. Conclusion: It can be concluded that pituitary enlargement and PRL cell hyperplasia in pregnant women may occur without neovascularization and increased VEGF immunoexpression. Mención de responsabilidad : Fabio Rotondo, Angelo Rotondo, Mark Jentoft, Bernd W Scheithauer, Luis V Syro, Jorge H Donado, James E Tarara, Kalman Kovacs Referencia : Hormones. 2013;12(2):292-7. DOI (Digital Object Identifier) : 10.14310/horm.2002.1413 PMID : 23933698 En línea : https://link.springer.com/article/10.14310/horm.2002.1413 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3699 Microvessel density and VEGF expression in pituitaries of pregnant women [documento electrónico] / Jorge Hernando Donado Gómez, ; Luis Vicente Syro Moreno, . - 2013.
Obra : Hormones
Idioma : Inglés (eng)
Palabras clave : Angiogenesis Immunohistochemistry Pituitary Pregnancy Vascular endothelial growth factor Resumen : Objective: In pregnant women, the pituitary is enlarged and the prolactin (PRL) secreting cells increase in size and number. This PRL cell hyperplasia is associated with hyperprol-actinemia. The aim of the present work was to investigate adenohypophysial vascularization and immunoexpression of vascular endothelial growth factor (VEGF) in pituitaries of pregnant and post-partum women and compare the results with age-matched adenohypophyses of non pregnant women who had no endocrine diseases. Design: Pituitaries (n=18) obtained by autopsy from female patients of reproductive age who had died during pregnancy, after abor- tion or during post-partum were immunostained for CD-34 and VEGF using the streptavidin-biotin-peroxidase complex method. Results: The results showed that microvessel densities and VEGF immunoexpression in the adenohypophyses of pregnant and post-partum women were similar to those found in the control pituitaries. Conclusion: It can be concluded that pituitary enlargement and PRL cell hyperplasia in pregnant women may occur without neovascularization and increased VEGF immunoexpression. Mención de responsabilidad : Fabio Rotondo, Angelo Rotondo, Mark Jentoft, Bernd W Scheithauer, Luis V Syro, Jorge H Donado, James E Tarara, Kalman Kovacs Referencia : Hormones. 2013;12(2):292-7. DOI (Digital Object Identifier) : 10.14310/horm.2002.1413 PMID : 23933698 En línea : https://link.springer.com/article/10.14310/horm.2002.1413 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3699 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000272 AC-2013-040 Archivo digital Producción Científica Artículos científicos Disponible
Título : Aggressive silent corticotroph adenoma progressing to pituitary carcinoma : the role of temozolomide therapy Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2011 Títulos uniformes : Hormones Idioma : Inglés (eng) Palabras clave : Carcinoma MGMT pituitary adenoma temozolomide treatment Resumen : Temozolomide (TMZ) has recently been recommended as a novel approach in the management of aggressive pituitary tumors. Herein, we present the case of a 43-year-old man with a 20-year history of silent subtype 2 pituitary corticotroph adenoma. Nine surgical resections and radiotherapy had failed to provide a cure. Morphological evaluation of the tumor revealed a mildly pleomorphic adenoma, the cells of which showed low-level cell proliferative activity with Ki67, increased topoisomerase II alpha index and conclusive O-6-methylguanine-DNA methyltransferase (MGMT) as well as vascular endothelial growth factor (VEGF) immunoreactivity. Given its aggressive behavior and failure of conventional therapy, TMZ was administered. The treatment was continued even after MGMT immunopositivity was identified, but failed to decrease MGMT immunoexpression and exerted no morphologic effect. Examination of the lesion after TMZ therapy showed neither morphologic nor immunohistochemical alterations. In our case, TMZ administration, despite changing the TMZ dosing regimen to prompt a drug response, was incapable of depleting MGMT stores. Mención de responsabilidad : Olga Moshkin, Luis V Syro, Bernd W Scheithauer, Leon D Ortiz, Camilo E Fadul, Humberto Uribe, Ricardo Gonzalez, Michael Cusimano, Eva Horvath, Fabio Rotondo, Kalman Kovacs Referencia : Hormones (Athens). 2011 Apr-Jun;10(2):162-7. DOI (Digital Object Identifier) : 10.14310/horm.2002.1307 PMID : 21724542 En línea : https://link.springer.com/article/10.14310/horm.2002.1307 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3549 Aggressive silent corticotroph adenoma progressing to pituitary carcinoma : the role of temozolomide therapy [documento electrónico] / Luis Vicente Syro Moreno, . - 2011.
Obra : Hormones
Idioma : Inglés (eng)
Palabras clave : Carcinoma MGMT pituitary adenoma temozolomide treatment Resumen : Temozolomide (TMZ) has recently been recommended as a novel approach in the management of aggressive pituitary tumors. Herein, we present the case of a 43-year-old man with a 20-year history of silent subtype 2 pituitary corticotroph adenoma. Nine surgical resections and radiotherapy had failed to provide a cure. Morphological evaluation of the tumor revealed a mildly pleomorphic adenoma, the cells of which showed low-level cell proliferative activity with Ki67, increased topoisomerase II alpha index and conclusive O-6-methylguanine-DNA methyltransferase (MGMT) as well as vascular endothelial growth factor (VEGF) immunoreactivity. Given its aggressive behavior and failure of conventional therapy, TMZ was administered. The treatment was continued even after MGMT immunopositivity was identified, but failed to decrease MGMT immunoexpression and exerted no morphologic effect. Examination of the lesion after TMZ therapy showed neither morphologic nor immunohistochemical alterations. In our case, TMZ administration, despite changing the TMZ dosing regimen to prompt a drug response, was incapable of depleting MGMT stores. Mención de responsabilidad : Olga Moshkin, Luis V Syro, Bernd W Scheithauer, Leon D Ortiz, Camilo E Fadul, Humberto Uribe, Ricardo Gonzalez, Michael Cusimano, Eva Horvath, Fabio Rotondo, Kalman Kovacs Referencia : Hormones (Athens). 2011 Apr-Jun;10(2):162-7. DOI (Digital Object Identifier) : 10.14310/horm.2002.1307 PMID : 21724542 En línea : https://link.springer.com/article/10.14310/horm.2002.1307 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3549 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000118 AC-2011-003 Archivo digital Producción Científica Artículos científicos Disponible
Título : Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2009 Títulos uniformes : Hormones Idioma : Inglés (eng) Palabras clave : MGMT Neoplasm Pathology Pituitary Temozolomide Resumen : The patient was a 70-year-old man with a recurrent pituitary tumor. Three surgeries were performed but the tumor recurred. Based on histologic, immunohistochemical and ultrastructural studies, the diagnosis of oncocytic gonadotrophic pituitary adenoma was made. The tumor was a macroadenoma partly immunopositive for LH. Immunohistochemistry for O6 Methylguanine-DNA Methyl-Transferase (MGMT) showed an admixture of immunopositive and immunonegative cells. After recurrence following operations, the patient was treated with Temozolomide, an imidazotetrazine derivative, DNA-alkylating drug. Following Temozolomide administration the MRI demonstrated significant tumor necrosis. A few months later, the patient died of massive pulmonary embolism. No autopsy was performed. The present case indicates that benign, typically slow-growing pituitary adenomas of oncocytic gonadotrophic type may respond to Temozolomide even when the tumor consists of an admixture of MGMT immunopositive and immunonegative cells. Mención de responsabilidad : Luis V Syro, Bernd W Scheithauer, Leon D Ortiz, Camilo E Fadul, Eva Horvath, Fabio Rotondo, Kalman Kovacs Referencia : Hormones (Athens). 2009 Oct-Dec;8(4):303-6. DOI (Digital Object Identifier) : 10.14310/horm.2002.1247 PMID : 20045804 En línea : https://link.springer.com/article/10.14310/horm.2002.1247 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4443 Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma [documento electrónico] / Luis Vicente Syro Moreno, . - 2009.
Obra : Hormones
Idioma : Inglés (eng)
Palabras clave : MGMT Neoplasm Pathology Pituitary Temozolomide Resumen : The patient was a 70-year-old man with a recurrent pituitary tumor. Three surgeries were performed but the tumor recurred. Based on histologic, immunohistochemical and ultrastructural studies, the diagnosis of oncocytic gonadotrophic pituitary adenoma was made. The tumor was a macroadenoma partly immunopositive for LH. Immunohistochemistry for O6 Methylguanine-DNA Methyl-Transferase (MGMT) showed an admixture of immunopositive and immunonegative cells. After recurrence following operations, the patient was treated with Temozolomide, an imidazotetrazine derivative, DNA-alkylating drug. Following Temozolomide administration the MRI demonstrated significant tumor necrosis. A few months later, the patient died of massive pulmonary embolism. No autopsy was performed. The present case indicates that benign, typically slow-growing pituitary adenomas of oncocytic gonadotrophic type may respond to Temozolomide even when the tumor consists of an admixture of MGMT immunopositive and immunonegative cells. Mención de responsabilidad : Luis V Syro, Bernd W Scheithauer, Leon D Ortiz, Camilo E Fadul, Eva Horvath, Fabio Rotondo, Kalman Kovacs Referencia : Hormones (Athens). 2009 Oct-Dec;8(4):303-6. DOI (Digital Object Identifier) : 10.14310/horm.2002.1247 PMID : 20045804 En línea : https://link.springer.com/article/10.14310/horm.2002.1247 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4443 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000943 AC-2009-031 Archivo digital Producción Científica Artículos científicos Disponible
